Form 4/A for ZURA Zura Bio Ltd
Accepted 2024-09-06 00:00:00 ET · period of report 2024-04-22 · accession 0001415889-24-023026 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AI | 2024-09-06 | 2024-04-22 | ZURA | Howell Michael | See Remarks | A - Grant | $3.13 | +7,987 | 7,987 | New | +$25.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A ordinary shares | 2024-04-22 | A | A | 7,987 | $3.13 | 7,987 | I By corporation | — | — | (F2) These shares were acquired in a private placement transaction pursuant to the terms of that certain Securities Purchase Agreement, dated as of April 18, 2024, between the Issuer and Mountaineer Biosciences, Inc. ("Mountaineer") at a purchase price of $3.13 per share. (F3) These shares are beneficially owned by Mountaineer. The Reporting Person is the Co-Founder of Mountaineer and, as such, has the power to vote and dispose of the ordinary shares held by Mountaineer. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |